EPO Could Revoke Key Affy Patent as the Validity of Core Microarray IP Is Questioned | GenomeWeb
The European Patent Office has taken steps to revoke a 13-year-old, foundational Affymetrix patent in Europe after eight years of opposition from firms including Multilyte, Oxford Gene Technology, and Incyte Pharmaceuticals, BioArray News has learned.
 
According to EPO documents, the opposition division of the EPO decided to revoke European Patent No. 0619321, “Method and apparatus for investigating polynucleotide or amino acid sequences,” on June 20.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.